title: A case of interferon-α-induced pulmonary arterial hypertension after living donor liver transplantation.
abstract: Pulmonary arterial hypertension (PAH) is a progressive and life-threatening disease characterized by elevated pulmonary vascular resistance, which results in right-heart failure. We present a case of interferon (IFN)-α-induced PAH developed after living donor liver transplantation. Although IFN is categorized as a "possible" risk factor for PAH in the current international classification, it is still under recognized. Moreover, the prognosis of IFN-induced PAH is poor in the limited number of published cases. In our case, we achieved good outcome by the withdrawal of IFN and administration of combination therapy using tadalafil, beraprost, and treprostinil. Since IFN is an important treatment option in current medical therapy, its contribution to the pathogenesis of PAH should be taken into consideration. In conclusion, our case suggests the importance of PAH screening in patients treated with IFN.
authors.affiliation: Department of Cardiovascular Medicine, The University of Tokyo Graduate School of Medicine, Hongo 7-3-1, Bunkyo-ku, Tokyo, 113-8655, Japan.
authors.forename: Toshiyuki
authors.initials: T
authors.lastname: Ko
authors.affiliation: Department of Cardiovascular Medicine, The University of Tokyo Graduate School of Medicine, Hongo 7-3-1, Bunkyo-ku, Tokyo, 113-8655, Japan. hatanoma@pg8.so-net.ne.jp.
authors.forename: Masaru
authors.initials: M
authors.lastname: Hatano
authors.affiliation: Department of Cardiovascular Medicine, The University of Tokyo Graduate School of Medicine, Hongo 7-3-1, Bunkyo-ku, Tokyo, 113-8655, Japan.
authors.forename: Daisuke
authors.initials: D
authors.lastname: Nitta
authors.affiliation: Department of Cardiovascular Medicine, The University of Tokyo Graduate School of Medicine, Hongo 7-3-1, Bunkyo-ku, Tokyo, 113-8655, Japan.
authors.forename: Hironori
authors.initials: H
authors.lastname: Muraoka
authors.affiliation: Department of Cardiovascular Medicine, The University of Tokyo Graduate School of Medicine, Hongo 7-3-1, Bunkyo-ku, Tokyo, 113-8655, Japan.
authors.forename: Shun
authors.initials: S
authors.lastname: Minatsuki
authors.affiliation: Department of Cardiovascular Medicine, The University of Tokyo Graduate School of Medicine, Hongo 7-3-1, Bunkyo-ku, Tokyo, 113-8655, Japan.
authors.forename: Teruhiko
authors.initials: T
authors.lastname: Imamura
authors.affiliation: Department of Cardiovascular Medicine, The University of Tokyo Graduate School of Medicine, Hongo 7-3-1, Bunkyo-ku, Tokyo, 113-8655, Japan.
authors.forename: Toshiro
authors.initials: T
authors.lastname: Inaba
authors.affiliation: Department of Cardiovascular Medicine, The University of Tokyo Graduate School of Medicine, Hongo 7-3-1, Bunkyo-ku, Tokyo, 113-8655, Japan.
authors.forename: Hisataka
authors.initials: H
authors.lastname: Maki
authors.affiliation: Department of Cardiovascular Medicine, The University of Tokyo Graduate School of Medicine, Hongo 7-3-1, Bunkyo-ku, Tokyo, 113-8655, Japan.
authors.forename: Atsushi
authors.initials: A
authors.lastname: Yao
authors.affiliation: Department of Cardiovascular Medicine, The University of Tokyo Graduate School of Medicine, Hongo 7-3-1, Bunkyo-ku, Tokyo, 113-8655, Japan.
authors.forename: Koichiro
authors.initials: K
authors.lastname: Kinugawa
authors.affiliation: Department of Cardiovascular Medicine, The University of Tokyo Graduate School of Medicine, Hongo 7-3-1, Bunkyo-ku, Tokyo, 113-8655, Japan.
authors.forename: Issei
authors.initials: I
authors.lastname: Komuro
mesh_terms: D000959:Antihypertensive Agents / Q000627:therapeutic use; D062186:Arterial Pressure / Q000187:drug effects*; D004359:Drug Therapy, Combination; D011464:Epoprostenol / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D006976:Hypertension, Pulmonary / Q000139:chemically induced* / Q000175:diagnosis / Q000503:physiopathology; D007155:Immunologic Factors / Q000009:adverse effects*; D016898:Interferon-alpha / Q000009:adverse effects*; D016031:Liver Transplantation / Q000009:adverse effects*; D019520:Living Donors; D008297:Male; D008875:Middle Aged; D011651:Pulmonary Artery / Q000187:drug effects* / Q000503:physiopathology; D000068581:Tadalafil / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000959:Antihypertensive Agents; D007155:Immunologic Factors; D016898:Interferon-alpha; C048081:beraprost; D000068581:Tadalafil; D011464:Epoprostenol; C427248:treprostinil
keywords: Interferon; Pulmonary arterial hypertension; Treprostinil